Tnbc her2 neg stage 1 grade 3 28mm. Is carboplatin and docetaxel x 6 the correct regime? Triple negative?

The short version: carboplatin plus docetaxel for six cycles is a standard regimen for stage I triple-negative breast cancer, but the evidence for its superiority over other options is thin and comes from studies that do not match your exact situation.

Yes, triple-negative breast cancer (TNBC) is the correct diagnosis for a tumor that is HER2-negative and does not express estrogen or progesterone receptors. Your tumor is 28 mm (stage I, grade 3), which puts it in a high-risk category despite the early stage.

The TNT trial (2018) compared carboplatin alone to docetaxel alone in 376 patients with advanced TNBC and found no significant difference in response rates: 31.4% for carboplatin versus 34.0% for docetaxel [1]. That trial tested single agents, not the combination you are asking about, and it studied advanced disease, not stage I. The combination of carboplatin plus docetaxel has been tested in a phase II trial (2013) for stage II/III TNBC, where it produced a 42% pathological complete response rate when given with bevacizumab [2]. That trial was single-arm, funded by the manufacturer of bevacizumab, and studied a more advanced stage than yours.

The evidence for this regimen in stage I TNBC specifically is absent from the records here. No trial has compared carboplatin plus docetaxel to other standard regimens (like anthracycline-based chemotherapy) in stage I disease with hard clinical endpoints like overall survival. The studies that exist use surrogate endpoints like pathological complete response, which does not always translate to long-term survival benefit.

The toxicity is substantial. In the phase II trial, 71% of patients had grade 4 neutropenia and 9% had febrile neutropenia [2]. The combination also carries risks of neuropathy, fatigue, and blood clots. A case report from 2020 describes a patient who developed digital ischemia requiring amputation after receiving carboplatin, docetaxel, and pembrolizumab [3], though this is a single case and causality is uncertain.

If you have a BRCA mutation, the picture changes. The OlympiA trial (2021) showed that adjuvant olaparib, a PARP inhibitor, improved invasive disease-free survival in high-risk BRCA-mutated HER2-negative breast cancer with a hazard ratio of 0.58 [4]. That trial studied a different population (stage II-III, not stage I) and a different drug, but it suggests that BRCA testing could open a more targeted option.

My call: carboplatin plus docetaxel for six cycles is a reasonable but unproven regimen for stage I TNBC. The evidence does not show it is superior to other standard options, and the toxicity is real. Ask your oncologist whether a less toxic regimen or a clinical trial is available. Confidence: low.